Researchers have reported initial findings from a public-private partnership between the ECOG-ACRIN Cancer Research Group and Caris Life Sciences to improve recurrence risk assessment in early-stage breast cancer using artificial intelligence (AI). They are pairing ECOG-ACRIN’s extensive clinical trial expertise and biorepository resources with Caris’ comprehensive MI Cancer Seek® whole exome and whole transcriptome profiling, whole slide imaging, and advanced machine learning platforms. New multimodal–multitask deep learning algorithms were trained on histopathologic imaging, clinical data, and molecular profiling data from over 4,000 patient cases in the biorepository of the groundbreaking TAILORx cancer clinical trial, one of the world’s largest such resources. Analyses of these AI-driven models demonstrated they were more effective than existing methods for assessing recurrence risk. This research highlights the potential of AI to support more personalized treatment decisions in early-stage breast cancer. Such a level of multimodal integration is unprecedented at this scale in the prognostication of early breast cancer. 

Researchers at New York University Abu Dhabi (NYUAD) have developed Spheromatrix, a simple and low-cost technology that enables tumor models to be grown, frozen, and stored for future use in cancer drug testing.

Vanderbilt University and EPB of Chattanooga, home of America’s most comprehensive quantum commercialization infrastructure, today announced plans to establish the Institute for Quantum Innovation, further positioning Chattanooga—and Tennessee—as a national hub for advancing quantum science and technology.  

Like a growing vine, a new robotic gripper can snake around and lift a variety of objects, including a glass vase and a watermelon, offering a gentler approach than conventional gripper designs. A larger version of the robo-tendrils can also safely lift a human out of bed.